Blood Pressure And Metabolic Effects Of Acetyl-l-Carnitine In Type 2 Diabetes: DIABASI Randomized Controlled Trial
Notes for this study:
||mg/dL Mean and SD. Placebo: before 0.94 ± 0.2, after 0.95 ± 0.2. Carnitine: before 0.93 ± 0.2, after 0.93 ± 0.2.
|Number of Subjects
In a randomized, double-blind, placebo-controled trial, 229 participants with hypertension and dyslipidemic type 2 diabetes took 1000 mg of acetyl-l-carnitine twice daily in addition to simvastatin, or only simvastatin for 6 months.
The primary outcome was systolic blood pressure, and there wasn't an apparent benefit, nor for diastolic blood pressure, weight, HbA1c, insulin, insulin sensitivity, glucose disposal rate, lipid profile, or kidney function.
There weren't notable differences in adverse events.